There is a gender chasm when it comes to the male-female breakdown of the financial advisers and portfolio managers working around the world today, and that imbalance could be having a negative impact on investor returns.
According to Morningstar, which looked at more than 26,000 fund managers registered in 56 countries, only a fifth of funds have at least one female manager, even though women are more likely to have earned a chartered financial analyst credential than their male counterparts.
Top Heal Care Stocks To Own For 2018: Arch Coal, Inc. (ARCH)
- [By Ben Levisohn]
The VanEck Vectors Coal ETF has gained 1.1% to $12.28 at 2:01 p.m. today, while Arch Coal (ARCH), which resumed listed trading yesterday after emerging from bankruptcy, has fallen 3% to $62.98.
Top Heal Care Stocks To Own For 2018: GTx Inc.(GTXI)
- [By Roberto Pedone]
One biopharmaceutical player that’s rapidly moving within range of triggering a major breakout trade is GTx (GTXI), which is dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical condition. This stock has been hammered by the bears so far in 2013, with shares off sharply by 53%.
If you look at the chart for GTx, you’ll notice that this stock recently gapped down sharply from over $4 to below $1.50 a share with heavy downside volume. Following that gap down, shares of GTXI have rebounded sharply and started to uptrend, with the stock moving higher from its low of $1.31 to its recent high of $1.96 a share. During that move, shares of GTXI have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GTXI within range of triggering a major breakout trade.
Traders should now look for long-biased trades in GTXI if it manages to break out above some near-term overhead resistance at $1.96 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.35 million shares. If that breakout triggers soon, then GTXI will set up to re-fill some of its previous gap down zone from August that started just above $4 a share. Some possible upside targets if GTXI gets into that gap with volume are $2.50 to $3 a share, or possibly even $3.50 a share.
Traders can look to buy GTXI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.50 a share. One can also buy GTXI off strength once it takes out $1.96 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top Heal Care Stocks To Own For 2018: Synchronoss Technologies Inc.(SNCR)
- [By Lisa Levin]
Synchronoss Technologies, Inc. (NASDAQ: SNCR) shares dropped 39 percent to $10.27 after Siris Capital disclosed that it is no longer interested in an all cash takeover of the company. Synchronoss Technologies said that it continues to explore full range of alternatives, including sale.
- [By Jim Robertson]
On Tuesday, our Elite Opportunity Pronewsletter suggested going long on small cap cloud software and services stock Synchronoss Technologies (NASDAQ: SNCR):
- [By Lisa Levin]
In trading on Wednesday, financial shares fell 1.72 percent. Meanwhile, top losers in the sector included Whitestone REIT (NYSE: WSR), down 8 percent, and Synchronoss Technologies, Inc. (NASDAQ: SNCR), down 7 percent.
Top Heal Care Stocks To Own For 2018: Pacira Pharmaceuticals, Inc.(PCRX)
- [By Lisa Levin]
Pacira Pharmaceuticals Inc (NASDAQ: PCRX) shares were also up, gaining 17 percent to $39.80. Pacira Pharmaceuticals reported preliminary 2016 revenue of $276.4 million.
- [By Chris Lange]
Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) has announced preliminary unaudited total revenues and net product sales for Exparel for the fourth quarter and the full year. Total revenues were $72.9 million and $276.4 million for the fourth quarter and full year, respectively. Exparel net product sales were $71.4 million and $239.9 million for the same periods, respectively. The consensus estimates from Thomson Reuters were calling for revenues of $72.56 million in the fourth quarter and $276.09 million in the full year.